ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

BI 3821001

A development code.

Its studies are led by Boehringer Ingelheim.

Furthest: phase 1, since Mar 31, 20262 company-led studies, 1 open or runningNext primary completion: Jun 22, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim21 open or runningphase 1since Mar 31, 2026Mar 31, 2026Jun 22, 2027phase 1 · NCT07908004

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 31, 2026First study: phase 1 study in HealthyFirst studyNCT07526194 · 72 enrolled · Germany
  2. Oct 26, 2026Phase 1 study in HealthyNCT07908004 · 40 planned · Germany

Ahead

  1. Jun 22, 2027Primary completion: phase 1 study in HealthyNCT07908004

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07908004Healthy · Germany1RecruitingJun 22, 202740
NCT07526194Healthy · Germany1CompletedSep 30, 202672

How it is read

Names in the registry

  • “BI 3821001”, 2 entries

Codes read as this program: BI3821001.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.